Chronic Rhinosinusitis denials in California external review
In the California DMHC record, independent physician reviewers decided 117 published external-review cases involving chronic rhinosinusitisand overturned the plan’s denial in 76.9%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for chronic rhinosinusitis
| Treatment | Decisions | Overturned |
|---|---|---|
| Balloon Ostial Dilation | 20 | 85% |
| Balloon Ostial Dilation Of The Frontal And Sphenoid Sinuses | 16 | 100% |
| Balloon Sinus Ostial Dilation | 15 | 80% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 99 | 87.9% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 18 | 16.7% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for Nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation); maxillary sinus ostium, trans-nasal or via canine fossa, nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation); frontal and sphenoid sinus ostia, and nasal/sinus endoscopy, surgical with ethmoidectomy; partial (anterior), with the approved submucous resection inferior turbinate, partial or complete, any method. Balloon dilation of the sinuses can be beneficial for patients with either recurrent acute, or chronic rhinosinusitis. Balloon dilation of the sinuses offers a significant benefit over traditional functional endoscopic sinus surgery as it carries less morbidity and can frequently be accomplished in an office setting.
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement for any or all of the components of an endoscopic procedure (bilateral ostial dilation of maxillary sinuses; bilateral balloon ostial dilation of frontal and sphenoid sinuses; and bilateral partial (anterior) nasal/sinus endoscopy, surgical with ethmoidectomy). Balloon dilation of the sinuses (BDS) is typically performed on patients with either recurrent acute rhinosinusitis (RARS) or chronic rhinosinusitis (CRS). BDS offers a significant benefit over traditional functional endoscopic sinus surgery (FESS) as it carries less morbidity and can frequently be accomplished in an office setting. BDS is recommended for patients who meet strict diagnostic criteria for rhinosinusitis and are refractory to maximal medical management, such as intranasal saline, topical steroids, and antibiotics.
Where the denial was upheld
The patient is a 41-year-old male with chronic eye pain and chronic rhinosinusitis. The records provided include multiple notes from several physicians with different specialties. He has had problems with chronic bilateral eye pain (also referred to variously as retro-orbital pain and atypical facial pain) for many years. He has had several surgeries, received neuro-ganglion blocks, and takes oral analgesics on a regular basis for this problem. There are detailed notes related to possible adverse affects experienced by the patient with the use of Neurontin and gabapentin. There are two physician dictations regarding this patient’s sinus disease history. In October 2004 it is noted that the patient had a history of nasal and paranasal sinus polyposis.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for surgical procedures including balloon dilation of the maxillary, frontal, and/or sphenoid sinus ostia and/or turbinate resection. Balloon dilation of the sinuses can be beneficial for patients with either recurrent acute, or chronic rhinosinusitis. Balloon dilation of the sinuses offers a significant benefit over traditional functional endoscopic sinus surgery as it carries less morbidity and can frequently be accomplished in an office setting. Balloon dilation of the sinuses should only be recommended to patients who meet the criteria for the diagnosis of rhinosinusitis and who are refractory to maximal medical management including the use of intranasal saline, topical steroids, and antibiotics.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving chronic rhinosinusitis, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY